BACKGROUND: The pathobiology of @entity19857 is rooted in a peculiar inflammatory reaction to Malassezia spp. Both topical corticosteroids and antifungals are routinely used with success, either singly or in combination. OBJECTIVE: To assess the effect of a new combination therapy in this condition. METHODS: Eighteen @entity1 with @entity19857 were treated in a pilot double-blind trial with an anhydrous gel containing the combination of 2% @entity3102 and 0.05% @entity24813 (n = 9) or the unmedicated gel (n = 9). The products were applied once daily for 3 consecutive weeks. Disease severity was assessed at the start and weekly during treatment, as well as 2, 4 and 8 weeks after the end of treatment or at the time of recurrence. The overall clinical assessments were performed using a visual analogue scale. Objective measurements included squamometry X after harvesting the stratum corneum and the erythema index yielded by narrow-band reflectance spectrophotometry. Data were evaluated in an intent-to-treat analysis. RESULTS: The combination therapy yielded reductions in the overall clinical symptom severity of 49, 84 and 92% after 1, 2 and 3 weeks of treatment, respectively. The corresponding improvements with the placebo gel were significantly smaller (p < 0.01), reaching 23, 29 and 42% at successive 1-week intervals. At the end of the 3-week treatment, the clinical signs had completely subsided in 6/9 @entity1 treated with the medicated gel and in only 1/9 @entity1 using the placebo gel. Thus, the clinical response rate was significantly faster (p < 0.01) with the combination therapy than with the vehicle. Differences between the treatment groups using objective noninvasive assessments were also significantly (p < 0.01) in favor of the combination therapy. The squamometry X measurements showed 47, 67 and 74% improvements with the combination gel after 1, 2 and 3 weeks, respectively. The corresponding values with the placebo gel were 34, 46 and 53%, respectively. The erythema index was almost completely reduced to normal at week 2 of treatment in contrast with about 50% reduction with the unmedicated vehicle. None of the @entity1 reported any side effects. CONCLUSION: The combination of @entity3102 with @entity24813 in an anhydrous gel is well tolerated and proves to be significantly more effective than the vehicle for treating @entity19857 . The fast response to treatment and the limited additional improvement between weeks 2 and 3 of the treatment suggest that this combination product may be efficacious with once daily applications for 2 weeks. These data call for expanded studies comparing each single compound, the vehicle and the combination therapy.

A double-blind placebo-controlled study of XXXX + @entity24813 gel combination in the treatment of @entity19857 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity19857 :: ('MESH:D012628', 'Disease') :: ['facial seborrheic dermatitis', 'seborrheic dermatitis'] @entity3102 :: ('MESH:D007654', 'Chemical') :: ['ketoconazole'] @entity24813 :: ('MESH:D003898', 'Chemical') :: ['desonide']
@entity3102 :: (MESH:D007654,Chemical) :: ['ketoconazole']
